Targets › INHBB
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Jul 2027.
Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth,…. (UniProt, P09529)
Open in Phaseline: the race on INHBB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Massachusetts General Hospital | Activin ligand-trap biological therapy Activin ligand trap (sequesters activin A and activin B) | INHBA, INHBB | Phase 2 | Heart Failure With Preserved Ejection Fraction | Jul 2027 |
Heart Failure With Preserved Ejection Fraction (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.